|
|
|
* - may be subscription-only |
|
|
- Arbor Biotechnologies: FDA Orphan Drug and Rare
Pediatric Disease Designations Granted to ABO-101 for
the Treatment of Primary Hyperoxaluria Type 1 (PH1)
and Upcoming Presentations at the 20th Congress of the
International Pediatric Nephrology Association (IPNA)
More
- Broken String Biosciences: Launches Catalyst
Program to Shorten Gene Editing Therapy Development
by Months More
More
- CereVasc: Results of Groundbreaking Clinical Study
of the eShunt System in the Treatment of Elderly
Patients With Normal Pressure Hydrocephalus More
- Immuneering: Clinical Supply Agreement With
Regeneron Pharmaceuticals to Evaluate IMM-1-104 in
Combination With Libtayo (cemiplimab) More
- Invivyd: Partnership With Pro Football Coach Jim
Harbaugh to Elevate Awareness and Ongoing Impact of
COVID-19: Common, Not A Cold More
- Lifeward: Finalizes Personal Exoskeleton
Reimbursement Agreement With BARMER, Adding 8.5
Million Covered Lives in Germany More
- Merus: New England Journal of Medicine Publishes -
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive
Cancer More
- Partner Therapeutics: New England Journal of
Medicine Publishes Results of Global, Multicenter
eNRGy Study Evaluating Zenocutuzumab-zbco (BIZENGRI)
in NRG1+ cancer More
- Thermo Fisher Scientific: Launches International
CorEvitas Clinical Registry in Adolescent Alopecia
Areata More
- Vaxxas: Appoints Leading Global Vaccine Experts as
the Company Advances Its Needle-Free Vaccination
Technology Towards Late-Stage Clinical Trials More
|
|
|
|
Section
Sponsor:
|
 |
|
|
|
|
- Boston Scientific: Results for Fourth Quarter and
Full Year 2024 More
More
More
More*
- Hologic: Financial Results for First Quarter of
Fiscal 2025 More
- Lab Developer IQHQ Refinances Fenway, Brighton
Properties More*
- Mustang Bio Says It Needs Additional Funds to Avoid
Bankruptcy More*
- Petri Dish: VC Firm’s New $340M Seed Fund; Watertown
Biotech Raises $185M More*
- REEV: Raises $9.2M to Revolutionize Mobility
Assistance for Patients With Gait Disorders More
- 2seventy bio: Preliminary* Full-Year U.S. Abecma
Sales and Select Financial Results More
- X4 Pharmaceuticals: Strategic Restructuring to
Drive Value and Maximize Opportunity for Mavorixafor
in Chronic Neutropenia More
|
|
|
|
Section
Sponsor:
|
 |
|
|
|
|
- Broad:
Mutations in Two Gene Pairs Point to a Promising Drug
Target in 5 Percent of Adult Cancers More
- Dana-Farber: Cancer Vaccine Shows Promise for
Patients With Stage III and IV Kidney Cancer More
- JPM Wrap: RESI Conference and RESI/Big4Bio
Reception Attendees Optimistic for the Year Ahead More
- Moderna Picks Merck KGaA, Roivant Alum as
Marketing Chief More
- More on EyePoint Sharing More Mid-Stage Data for
Therapy Trying to Compete With Regeneron’s Eylea More*
- More on Qlaris Seeing Double as Drug Reduces Eye
Pressure in Pair of Phase 2 Trials More
- Nucleate: Revolutionizing Gene Therapy With
AI-Powered Capsid Engineering | Eric Kelsic, Dyno Tx Podcast
- Subscribe to LifeSci Startup for Updates on
US Startups More
- With First Drug
Now in the Clinic, Alys Eyes Megaround for Rest of
Pipeline More*
More
|
|
|
|
Section
Sponsor:
|
 |
|
|
| SECTION SPONSOR: |
 |
|
|
- Big4Bio:Boston Life Science Company
Directory More
|
NOTE:
EVENTS AND JOBS ARE FROM ALL BIG4BIO REGIONS
|
|
|
|
|
|
|
|
|
Section
Sponsor:
|
 |
|
|
|
|
- OPPORTUNITY: Senior Director, Integrated Marketing
& Communications - Remote More
- OPPORTUNITY: Clinical Development Leader - New York,
NY More
- OPPORTUNITY: Sales Executive - Hybrid More
- OPPORTUNITY: Senior Director of Business Development
- Remote More
- OPPORTUNITY: Vice President of North America Medical
Affairs - MA More
- OPPORTUNITY: Vice President of Sales &
Marketing, North America - Remote More
|
|
|
|
Section
Sponsor:
|
|
|
|
|
